grant

The Role of Neutrophil Heterogeneity and Molecular Mechanisms in Driving ALS

Organization UNIVERSITY OF MICHIGAN AT ANN ARBORLocation ANN ARBOR, UNITED STATESPosted 1 Jul 2024Deadline 30 Jun 2027
NIHUS FederalResearch GrantFY2025ALS pathologyALS patientsALS therapyALS treatmentAccelerationActive OxygenAirway failureAlzheimer beta-ProteinAlzheimer's Amyloid beta-ProteinAlzheimer's amyloidAlzheimer's disease patientAlzheimer's patientAmyloid (Aβ) plaquesAmyloid Alzheimer's Dementia Amyloid ProteinAmyloid Beta-PeptideAmyloid PlaquesAmyloid Protein A4Amyloid beta-ProteinAmyloid βAmyloid β-PeptideAmyloid β-ProteinAmyotrophic Lateral SclerosisAmyotrophic Lateral Sclerosis Motor Neuron DiseaseAmyotrophic Lateral Sclerosis patientsAnimal ModelAnimal Models and Related StudiesAssayAutomobile DrivingBioassayBiological AssayBiometricsBiometryBiostatisticsBleedingBloodBlood NeutrophilBlood PlasmaBlood Polymorphonuclear NeutrophilBlood Reticuloendothelial SystemBody TissuesCNS Nervous SystemCell BodyCell FunctionCell PhysiologyCell ProcessCellsCellular FunctionCellular PhysiologyCellular ProcessCentral Nervous SystemCessation of lifeClinicalCritical PathsCritical PathwaysDataDeathDegenerative Neurologic DisordersDevelopmentDiseaseDisease ProgressionDisorderDisseminated SclerosisEAEExperimental Allergic EncephalitisExperimental Allergic EncephalomyelitisExperimental Autoimmune EncephalitisExperimental Autoimmune EncephalomyelitisFlow CytofluorometriesFlow CytofluorometryFlow CytometryFlow MicrofluorimetryFlow MicrofluorometryFutureGehrig's DiseaseGenesGoalsHemorrhageHeterogeneityImmuneImmune responseImmune systemImmunesImmunologic SubtypingImmunophenotypingIn VitroIndividualInflammatoryLou Gehrig DiseaseLytotoxicityMagnetismMarrow NeutrophilMeasuresMediatingMedulla SpinalisMolecularMotorMotor CellMotor NeuronsMultiple SclerosisMuscle AtrophyMuscular AtrophyNerve CellsNerve DegenerationNerve UnitNervous System Degenerative DiseasesNeural CellNeural Degenerative DiseasesNeural degenerative DisordersNeuraxisNeuritic PlaquesNeurocyteNeurodegenerative DiseasesNeurodegenerative DisordersNeurologic Degenerative ConditionsNeuron DegenerationNeuronal InjuryNeuronsNeutrophil ActivationNeutrophil InfiltrationNeutrophil RecruitmentNeutrophilic GranulocyteNeutrophilic InfiltrateNeutrophilic LeukocyteOnset of illnessOxygen RadicalsPalsyParalysedParticipantPathogenesisPathogenicityPathway interactionsPatientsPeripheralPlasmaPlasma SerumPlayPlegiaPolymorphonuclear CellPolymorphonuclear LeukocytesPolymorphonuclear NeutrophilsPopulationPro-OxidantsProductionProteinsProtocolProtocols documentationPublishingReactive Oxygen SpeciesRespiratory FailureRespiratory physiologyReticuloendothelial System, Serum, PlasmaRoleSamplingSenile PlaquesSeverity of illnessSpeedSpinal CordSubcellular ProcessSurfaceTDP-43 aggregateTDP-43 aggregationTDP43 aggregateTDP43 aggregationTestingTissuesa beta peptideabetaagedamyloid betaamyloid beta plaqueamyloid-b plaqueamyloid-b proteinamyotrophic lateral sclerosis pathologyamyotrophic lateral sclerosis therapyamyotrophic lateral sclerosis treatmentautoimmune encephalomyelitisaxonal degenerationaβ plaquesbeta amyloid fibrilblood losscell typecompare to controlcomparison controlcomputer based predictioncored plaquecytokinecytotoxicitydegenerative axondegenerative diseases of motor and sensory neuronsdegenerative neurological diseasesdevelopmentaldiffuse plaquedisease modeldisease onsetdisease severitydisorder modeldisorder onsetdrivingeffective therapyeffective treatmentextracellularfALSfamilial ALSfamilial amyotrophic lateral sclerosisfirst responderflow cytophotometryfunctional statushost responseiPSiPSCiPSCsimmune system responseimmunoresponsein vivoinduced pluripotent cellinduced pluripotent stem cellinducible pluripotent cellinducible pluripotent stem cellinsular sclerosismagneticmigrationmodel of animalmotoneuronmotor neuron degenerationmouse modelmurine modelmuscle breakdownmuscle degradationmuscle deteriorationmuscle lossmuscle wastingnerve cell deathnerve cell lossneural degenerationneurodegenerationneurodegenerativeneurodegenerative illnessneurological degenerationneuron cell deathneuron cell lossneuron deathneuron injuryneuron lossneuronalneuronal cell deathneuronal cell lossneuronal deathneuronal degenerationneuronal lossneutrophilnew drug targetnew druggable targetnew markernew pharmacotherapy targetnew therapeutic targetnew therapy targetnovel biomarkernovel drug targetnovel druggable targetnovel markernovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetparalysisparalyticpathology in ALSpathwaypatient living with Alzheimer's diseasepatient suffering from Alzheimer's diseasepatient with Alzheimer'spatient with Alzheimer's diseaseperipheral bloodpredictive modelingrecruitrepairrepairedrespiratory functionresponsesALSscRNA sequencingscRNA-seqsingle cell RNA-seqsingle cell RNAseqsingle cell expression profilingsingle cell transcriptomic profilingsingle-cell RNA sequencingsocial rolesoluble amyloid precursor proteinsporadic ALSsporadic amyotrophic lateral sclerosistherapeutic agent developmenttherapeutic developmenttherapeutic targettrafficking
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

ABSTRACT
There is overwhelming evidence that the immune system plays a significant role in amyotrophic lateral

sclerosis (ALS) pathogenesis. However, information about the role of specific immune populations and the

underlying mechanisms is currently lacking. Neutrophils are innate immune cells that function as first-

responders to damage, including damage to neuronal tissue. These cells ultimately determine whether

damaged neurons undergo repair or whether damage is exacerbated. Additional damage can occur directly via

cytotoxicity or indirectly through the recruitment of other immune cell types, the release of pro-inflammatory

cytokines, and the suppression of repair mechanisms. Thus, neutrophils may play a central role in the

response to motor neuron damage in ALS. To support this, our previously published studies show that

neutrophils are increased in the blood of ALS patients, that these cells accumulate in the central nervous

system (CNS) of individuals with ALS, and that increased levels in the peripheral blood are associated with

shortened survival. In addition, preliminary data show that peripheral neutrophils are dysregulated in ALS with

increased expression of trafficking and activation markers. Finally, our predictive models of disease show that

neutrophil levels are the single best predictor of future ALS progression in patients. Therefore, I hypothesize

that neutrophils contribute to ALS pathology by accelerating motor neuron death and by suppressing pro-repair

immune responses in the CNS. To test this, I propose two Specific Aims which will assess the role of

neutrophils in ALS. In the first Aim, I will identify subpopulations of neutrophils or neutrophil-based mechanisms

that are associated with ALS progression and survival. To do this, I will use flow cytometry, single cell RNA-

Seq (scRNA-Seq), and analysis of neutrophil extracellular trap (NET) remnants to immunophenotype

neutrophils in the peripheral blood of control and ALS participants. Dysregulated pathways will first be

identified and then associated with ALS progression and survival using our existing biostatistical pipeline. In

the second Aim, I will identify the mechanisms by which neutrophils become activated and more pro-

inflammatory in ALS. To do so, I will culture primary and iPSC-derived neutrophils with and without ALS-

associated proteins such as TDP-43 aggregates. Activation and pro-inflammatory activity will be determined

via flow cytometry and assays for degranulation, reactive oxygen species release, and NET formation. Overall,

completion of these studies will elucidate mechanisms driving neutrophil-mediated damage in ALS and identify

potential therapeutic targets for future studies.

Grant Number: 5F31NS139629-02
NIH Institute/Center: NIH

Principal Investigator: Lillia Baird

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →